GLANDPharmaceuticals
Gland Pharma Ltd — Cash Flow Statement
₹1696.10
+0.56%
Gland Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 520.56 Cr | 598.54 Cr | 140.85 Cr | 268.65 Cr | — |
| Repayment Of Debt | -62.82 Cr | -777.31 Cr | -0.11 Cr | -0.14 Cr | — |
| Issuance Of Debt | 5.28 Cr | 21.03 Cr | 0.00 | — | — |
| Issuance Of Capital Stock | 2.49 Cr | 0.53 Cr | 21.50 Cr | 38.55 Cr | — |
| Capital Expenditure | -394.17 Cr | -398.26 Cr | -223.12 Cr | -522.12 Cr | — |
| End Cash Position | 2.56K Cr | 357.09 Cr | 1.91K Cr | 318.82 Cr | — |
| Beginning Cash Position | 357.09 Cr | 1.91K Cr | 318.82 Cr | 492.46 Cr | — |
| Effect Of Exchange Rate Changes | 13.13 Cr | 7.72 Cr | 3.00 Cr | 3.31 Cr | — |
| Changes In Cash | 2.19K Cr | -1.56K Cr | 1.59K Cr | -176.95 Cr | — |
| Financing Cash Flow | -433.48 Cr | -799.42 Cr | 14.92 Cr | 34.90 Cr | — |
| Interest Paid Cff | -30.59 Cr | -25.61 Cr | -6.29 Cr | -3.40 Cr | — |
| Cash Dividends Paid | -329.49 Cr | — | — | — | — |
| Net Common Stock Issuance | 2.49 Cr | 0.53 Cr | 21.50 Cr | 38.55 Cr | — |
| Common Stock Issuance | 2.49 Cr | 0.53 Cr | 21.50 Cr | 38.55 Cr | — |
| Net Issuance Payments Of Debt | -57.54 Cr | -756.28 Cr | -0.11 Cr | -0.14 Cr | — |
| Net Long Term Debt Issuance | -57.54 Cr | -756.28 Cr | -0.11 Cr | -0.14 Cr | — |
| Long Term Debt Payments | -62.82 Cr | -777.31 Cr | -0.11 Cr | -0.14 Cr | — |
| Long Term Debt Issuance | 5.28 Cr | 21.03 Cr | 0.00 | — | — |
| Investing Cash Flow | 1.70K Cr | -1.76K Cr | 1.21K Cr | -1.00K Cr | — |
| Interest Received Cfi | 156.49 Cr | 137.05 Cr | 160.60 Cr | 130.82 Cr | — |
| Net Investment Purchase And Sale | 1.94K Cr | -474.72 Cr | 1.27K Cr | -611.72 Cr | — |
| Sale Of Investment | 2.44K Cr | 265.33 Cr | 1.74K Cr | 1.07K Cr | — |
| Purchase Of Investment | -497.98 Cr | -740.05 Cr | -469.98 Cr | -1.68K Cr | — |
| Net Business Purchase And Sale | 0.00 | -1.02K Cr | 0.00 | — | — |
| Purchase Of Business | 0.00 | -1.02K Cr | 0.00 | — | — |
| Net Intangibles Purchase And Sale | -9.62 Cr | -8.33 Cr | -2.19 Cr | -10.79 Cr | — |
| Purchase Of Intangibles | -9.62 Cr | -8.33 Cr | -2.19 Cr | -10.79 Cr | — |
| Net PPE Purchase And Sale | -384.20 Cr | -389.16 Cr | -220.79 Cr | -510.93 Cr | — |
| Sale Of PPE | 0.34 Cr | 0.77 Cr | 0.14 Cr | 0.40 Cr | — |
| Purchase Of PPE | -384.54 Cr | -389.93 Cr | -220.93 Cr | -511.33 Cr | — |
| Operating Cash Flow | 914.73 Cr | 996.80 Cr | 363.97 Cr | 790.77 Cr | — |
| Taxes Refund Paid | -353.80 Cr | -306.15 Cr | -310.87 Cr | -406.51 Cr | — |
| Change In Working Capital | -6.06 Cr | -53.20 Cr | -417.94 Cr | -393.01 Cr | — |
| Change In Other Current Assets | -164.29 Cr | -5.10 Cr | 35.65 Cr | -138.08 Cr | — |
| Change In Payable | 26.90 Cr | -378.87 Cr | 120.98 Cr | 65.92 Cr | — |
| Change In Inventory | -19.92 Cr | 666.08 Cr | -759.63 Cr | 89.50 Cr | — |
| Change In Receivables | 42.29 Cr | -324.95 Cr | 179.97 Cr | -419.78 Cr | — |
| Other Non Cash Items | -171.20 Cr | -128.81 Cr | -116.67 Cr | -135.24 Cr | — |
| Provisionand Write Offof Assets | 0.77 Cr | 13.84 Cr | 0.00 | 3.79 Cr | — |
| Depreciation And Amortization | 377.87 Cr | 344.57 Cr | 146.74 Cr | 110.30 Cr | — |
| Amortization Cash Flow | 18.56 Cr | 18.69 Cr | 0.87 Cr | 0.45 Cr | — |
| Depreciation | 359.31 Cr | 344.57 Cr | 145.86 Cr | 109.85 Cr | — |
| Gain Loss On Investment Securities | -1.23 Cr | -0.35 Cr | -2.85 Cr | -4.49 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.01 Cr | -12.97 Cr | 2.36 Cr | -7.76 Cr | — |
| Gain Loss On Sale Of PPE | 0.03 Cr | -0.25 Cr | 0.08 Cr | 0.18 Cr | — |
| Net Income From Continuing Operations | 1.06K Cr | 1.13K Cr | 1.05K Cr | 1.62K Cr | — |
| Stock Based Compensation | — | — | 0.00 | 4.62 Cr | 15.53 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Gland Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.